

Improving the prescription of oral anticoagulants in atrial fibrillation

Pritchett, Ruth; Bem, Danai; Turner, Grace; Thomas, G Neil; Clarke, Joanne; Fellows, Rebecca; Lane, Deirdre; Jolly, Kate

DOI:

[10.1055/s-0038-1676835](https://doi.org/10.1055/s-0038-1676835)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Pritchett, R, Bem, D, Turner, G, Thomas, GN, Clarke, J, Fellows, R, Lane, D & Jolly, K 2019, 'Improving the prescription of oral anticoagulants in atrial fibrillation: A systematic review', *Thrombosis and Haemostasis*, vol. 119, no. 2, pp. 294-307. <https://doi.org/10.1055/s-0038-1676835>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 27/03/2019

CC BY-NC-ND 4.0 · Thromb Haemost 2019; 119(02): 294-307

DOI: 10.1055/s-0038-1676835

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Database: Ovid MEDLINE

- 1 Atrial Fibrillation/ or "atrial fibrillation."mp.
- 2 Atrial Flutter/ or "atrial flutter."mp.
- 3 ("auricular fibrillation" or "heart fibrillation" or "heart atrium fibrillation").ti,ab.
- 4 1 or 2 or 3
- 5 exp Anticoagulants/tu, th [Therapeutic Use, Therapy]
- 6 ((anticoagula\$ or antithrombotic\$1) adj2 (therapy or treatment or under-treatment or uptake or underus\$ or prescri\$ or prophylaxis or management or assessment or clinic\$1)).ti,ab.
- 7 exp Factor Xa Inhibitors/tu [Therapeutic Use]
- 8 exp Antithrombins/tu [Therapeutic Use]
- 9 ("direct thrombin inhibitor\$1" or DTI\$1 or "factor Xa inhibitor\$1" or "fxa inhibitor\$1" or NOAC\$1 or "novel oral anticoagulant\$1" or "new oral anticoagulant\$1" or "non-vitamin K antagonist\$1").ti,ab.
- 10 Dabigatran/ or ("dabigatran etexilate" or dabigatran or Pradaxa).ti,ab.
- 11 Rivaroxaban/ or (rivaroxaban or Xarelto).ti,ab.
- 12 (apixaban or Eliquis).ti,ab.
- 13 (edoxaban or Lixiana or Savaysa).ti,ab.
- 14 exp Coumarins/tu, th [Therapeutic Use, Therapy]
- 15 (4-hydroxyc?umarin\$1 or "Vitamin K antagonist" or VKA\$1).mp.
- 16 Warfarin/ or (warfarin or C?umadin or Jantoven or Marevan).ti,ab.
- 17 Dicumarol/ or (dic?umarol\$ or dic?umarin or Bis-Hydroxyc?umarin or bishydroxyc?umarin or Acadyl or Acavyl or Barac?umin or Cuma or Cumid or Dic?uma\$ or Dicumol or Dikumol or Dufalone or Kumoran or Melitoxi or Temparin or Trombosan).ti,ab.
- 18 Phenprocoumon/ or (phenproc?umon\$ or fenproc?umon or phenproc?umarol or Marc?umar or Falithrom).ti,ab.
- 19 Acenocoumarol/ or (acenoc?umarol or nic?umalon\$ or Sintrom or Ascumar or Acitrom or Mini-sintrom or Neo-sintrom or Sinkumar or Sinthrome or Sync?umar or Synthrom or Trombostop).ti,ab.
- 20 (tiocloamarol\$ or Apegmone).ti,ab.
- 21 Ethyl Biscoumacetate/ or ("ethyl bisc?umacetate" or carbethoxydic?umarol or ethyldic?umarol or dic?umacyl or Pelentan or Tromexan or Thrombolysan or Thrombarin or Neodic?umari\$).ti,ab.
- 22 ("indandione derivative\$1" or "non-c?umarin VKA\$1").ti,ab.
- 23 Phenindione/ or (phenindion\$ or fenindion\$ or Dindevan or Fenilin or Phenylene or Soluthrombine).ti,ab.
- 24 (clorindion\$ or chlorphenindone or Indaliton or Cumachlor).ti,ab.
- 25 (diphenadion\$ or difenadion\$ or diphenacin or Dipaxin or Diphac\$).ti,ab.
- 26 (fluindion\$ or Previscan).ti,ab.
- 27 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
- 28 Health Education/ or Health Promotion/ or "Outcome and Process Assessment (Health Care)"/ or Primary Health Care/ or Health Knowledge, Attitudes, Practice/ or "Outcome Assessment (Health Care)"/ or Program Evaluation/
- 29 Education, Professional/ or Education, Professional, Retraining/
- 30 Practice Patterns, Physicians'/ or Practice Guideline/ or Practice Patterns, Nurses'/ or Practice Guidelines as Topic/ or Practice Management/ or General Practice/ or Family Practice/
- 31 Medical Audit/ or Nursing Audit/
- 32 Reminder Systems/
- 33 exp Drug Therapy, Computer-Assisted/ed, mt, nu, td, ut [Education, Methods, Nursing, Trends, Utilization]
- 34 "Marketing of Health Services"/
- 35 Guideline Adherence/
- 36 Information Dissemination/ or "dissemination tool\$1".ti,ab.
- 37 Decision Support Techniques/ or Decision Support Systems, Clinical/
- 38 exp Decision Making/de [Drug Effects]
- 39 ("decision aid\$" or "decision support" or "decision making").ti,ab.
- 40 (intervention\$ or "local consensus process" or "education\$ material" or "education\$ outreach" or "education\$ meeting \$1" or "behavio?r\$ change\$1" or "perception change\$1" or "practice change\$1" or reminder\$1 or alert\$1 or "guideline\$1 implementation" or "guideline\$1 adherence" or "practice guideline\$1" or "practice pattern\$1" or audit or feedback or "evaluation feedback" or "information dissemination" or "software enhancement" or "software tool\$1" or "medical practice management software" or "stroke prevention" or "action and monitoring").ti,ab.

Supplementary Fig. S1 Sample search strategy.

41 ((education\$ or behavior\$ or prescri\$ or persuasive or informational or marketing or professional\$ or physician\$1 or clinician\$1 or doctor\$1 or practitioner\$1 or GP\$1 or pharmacist\$1 or multifaceted or multidisciplinary or "patient-mediated" or "patient-driven") adj2 (intervention\$1 or strateg\$ or program\$ or initiative\$1 or incentive\$1 or improv\$)).ti,ab.
 42 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41
 43 4 and 27 and 42
 44 limit 43 to humans

Supplementary Fig. S1 (Continued)

	Random sequence generation	Allocation concealment	Blinding of study participants	Blinding of investigators	Blinding of outcome assessment	Incomplete Primary outcome data	Incomplete Secondary outcome data	Handling missing data	Selective reporting
Bajorek, 2016 ⁵³	●	●	●	●	●	●	●	●	●
Arts, 2017 ⁵⁴	●	●	●	●	●	●	●	●	●
Holt, 2017 ⁵⁵	●	●	●	●	●	●	●	●	●

● = Low risk of bias; ● = Unclear; ● = Risk of bias.

Supplementary Fig. S2 Risk of bias in RCTs using the Cochrane Risk of Bias Tool.

	1	2	3	4	5	6	7	8	9	10	11	12	13
Jackson, 2004 ⁵⁶	●	NA	NA	●	●	●	●	●	●	●	NA	●	●
Touchette, 2008 ⁵⁷	●	●	●	●	●	●	●	●	●	NA	NA	●	●
Hendriks, 2010 ⁵⁹	●	●	●	●	●	●	●	●	NA	●	NA	●	●
Boriani, 2012 ⁶¹	●	NA	NA	●	●	●	●	●	●	NA	●	●	●
Cook, 2015 ⁶²	●	●	●	●	●	●	●	●	●	NA	NA	●	●

● = Low risk of bias; ● = Unclear; ● = Risk of bias; NA = not applicable.

Supplementary Fig. S3 Risk of bias in controlled studies using an adjusted Cochrane Risk of Bias Tool.

Criteria used:

1. How were different groups selected (e.g., from the same source, at the same time).
2. For historical controlled studies also consider if the two sets of patients are comparable.
3. For historical controlled studies also consider: 1. changes in the diagnostic criteria; 2. differences in concomitant standards of care over time (e.g., new guidelines).
4. Were different groups similar at baseline on important characteristics that could affect outcomes (e.g., demographics, risk factors, co-morbid conditions)?
5. Did the authors report that the sample size was sufficiently large to be able to detect a difference in the main outcome between groups with at least 80% power?
6. Blinding of outcome assessment.
7. Was blinding of outcome assessment the same for all groups?
8. Incomplete primary outcome data.
9. Incomplete secondary outcome data.
10. Handling missing data (e.g., intention to treat).
11. Was follow-up time and method of follow-up the same in both groups?
12. Selective reporting (e.g., only certain outcomes, no adverse events).
13. Other sources of bias.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Falces, 2011 ⁶³	✓	✓	CD	✓	x	NA	✓	✓	✓	x	✓	NR	✓	✓

✓ = YES; x = NO; CD = cannot determine; NA = not applicable; NR = not reported

Supplementary Fig. S4 Risk of bias in cross-sectional studies using the NIH National Heart, Lung and Blood Institute Quality Assessment Tool for observational cohort and cross-sectional studies.

Criteria used:

1. Was the study question or objective clearly stated?
2. Were eligibility/selection criteria for the study population pre-specified and clearly described?
3. Was the participation rate of eligible persons at least 50%?
4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study pre-specified and applied uniformly to all participants?
5. Was a sample size justification, power description, or variance and effect estimates provided?
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?
7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?
8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
10. Was the exposure(s) assessed more than once over time?
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
12. Were the outcome assessors blinded to the exposure status of participants?
13. Was loss to follow-up after baseline 20% or less?
14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Sobreques, 2002 ⁶⁴	✓	x	✓	CD	NR	x	CD	✓	NR	✓	CD	✓	x	✓
Lowdon, 2004 ⁶⁵	✓	CD	✓	CD	CD	✓	✓	x	CD	CD	NA	CD	x	✓
Bajorek, 2005 ⁶⁶	✓	✓	x	x	✓	✓	✓	✓	CD	✓	✓	✓	x	✓
Bo, 2007 ⁶⁷	✓	✓	x	✓	✓	✓	✓	✓	CD	✓	✓	✓	x	✓
Coll-Vinent, 2007 ⁶⁸	✓	✓	✓	CD	CD	✓	✓	✓	CD	✓	✓	✓	x	✓
Jackson, 2011 ⁶⁹	✓	✓	x	x	CD	✓	✓	✓	✓	✓	CD	✓	x	✓
Robson, 2014 ⁷¹	✓	✓	x	✓	CD	✓	✓	✓	CD	✓	NA	✓	✓	✓
Oliveira, 2014 ⁷⁰	✓	✓	x	CD	CD	✓	CD	✓	NR	CD	x	x	x	✓
Das, 2015 ⁷²	✓	✓	✓	x	CD	✓	✓	✓	NA	✓	✓	✓	x	✓
Hsieh, 2016 ⁷³	✓	x	x	CD	CD	✓	✓	✓	CD	✓	CD	✓	✓	✓
Wang, 2017 ⁷⁴	✓	✓	x	CD	CD	✓	✓	✓	CD	✓	✓	✓	x	NA

✓ = YES; x = NO; CD = cannot determine; NA = not applicable; NR = not reported

Supplementary Fig. S5 Risk of bias in before-after studies using an adapted form of the NIH National Heart, Lung and Blood Institute Quality Assessment Tool for before-after studies with no control group.

Criteria used:

1. Was the study question or objective clearly stated?
2. Were eligibility/selection criteria for the study population pre-specified and clearly described?
3. Were the participants in the study representative of those who would be eligible for the service/intervention in the general or clinical population of interest?
4. Were all eligible participants that met the pre-specified entry criteria enrolled?
5. Was the sample size sufficiently large to provide confidence in the findings?
6. Was the service/intervention clearly described and delivered consistently across the study population?
7. Was the duration of the intervention sufficient so that one could reasonably expect to see any changes in practice and/or behavior?
8. Were the outcome measures pre-specified, clearly defined, valid, reliable, and assessed consistently across all study participants?
9. Were the people assessing the outcomes blinded to the participants' interventions?
10. Was the length of follow-up sufficient so that one could reasonably expect to capture any changes in practice and/or behavior?
11. Was the loss to follow-up after baseline 20% or less? Were those lost to follow-up accounted for in the analysis?
12. Did the statistical methods examine changes in outcome measures from before to after the intervention? Were statistical tests done that provided p values for the pre-to-post changes?
13. Were outcome measures of interest taken multiple times before the intervention and multiple times after the intervention (i.e., did they use an interrupted time-series design)?
14. If the intervention was conducted at a group level (e.g., a whole hospital, a community, etc.) did the statistical analysis take into account the use of individual-level data to determine effects at the group level?

Supplementary Table S1 Excluded studies

Study	Reason for exclusion
Makowski 1994 ¹	Full text unavailable
Steffensen, 1997 ²	Ineligible outcome
Gaughan, 2000 ³	Not original data
Valeti, 2000 ⁴	Full text unavailable
Batty, 2001 ⁵	Ineligible outcome
O'Rourke 2001 ⁶	Ineligible study design
Elliot, 2002 ⁷	Ineligible outcome
Jackson, 2003 ⁸	Not original data
Batty, 2004 ⁹	Ineligible outcome
Alberts, 2004 ¹⁰	Ineligible study design
Kiechl, 2004 ¹¹	Ineligible study design
Claes, 2005 ¹²	Ineligible outcome
Wright, 2007 ¹³	Ineligible outcome
Schwarz, 2009 ¹⁴	Ineligible outcome
Albert, 2010 ¹⁵	Ineligible outcome
Bishop, 2011 ¹⁶	Ineligible outcome
Szabo, 2011 ¹⁷	Ineligible population
Boriani, 2011 ¹⁸	Not original data
Healicon, 2011 ¹⁹	Full text unavailable
Hendriks, 2012 ²⁰	Ineligible population
Boriani, 2012 ²¹	Not original data
Larsen, 2012 ²²	Full text unavailable
Skanes, 2013 ²³	Ineligible intervention
Samani, 2013 ²⁴	Ineligible outcome
Gadzhanova, 2013 ²⁵	Ineligible outcome
Arts, 2013 ²⁶	Ineligible study design

Supplementary Table S1 (Continued)

Study	Reason for exclusion
Jeng, 2013 ²⁷	Not original data
Beadles, 2014 ²⁸	Ineligible intervention
Po, 2014 ²⁹	Ineligible outcome
Grant, 2014 ³⁰	Ineligible outcome
Alkhalil, 2014 ³¹	Full text unavailable
Skolarus, 2014 ³²	Ineligible outcome
Sibai, 2014 ³³	Ineligible study design
Das, 2014 ³⁴	Not original data
Fuenzalida, 2015 ³⁵	Ineligible outcome
Daacke, 2015 ³⁶	Full text unavailable
Akhavain, 2015 ³⁷	Full text unavailable
Garber, 2015 ³⁸	Ineligible study design
Zheng, 2016 ³⁹	Ineligible intervention
Eckman, 2016 ⁴⁰	Ineligible outcome
Eckman, 2016 ⁴¹	Ineligible outcome
Abidi, 2016 ⁴²	Ineligible outcome
Lee, 2016 ⁴³	Ineligible study design
Rao, 2016 ⁴⁴	Ineligible study design
Willis, 2016 ⁴⁵	Ineligible study design
Czernik, 2016 ⁴⁶	Full text unavailable
Cloutier, 2016 ⁴⁷	Full text unavailable
Amiri, 2017 ⁴⁸	Ineligible outcome
Barmano, 2017 ⁴⁹	Ineligible outcome
Rose, 2017 ⁵⁰	Ineligible outcome
Karlsson, 2017 ⁵¹	Ineligible study design
Virdee, 2017 ⁵²	Ineligible study design

Supplementary Table S2 Outcome measures and results

Author	Outcome measure	Baseline or pre-intervention % (n)	Follow-up or post-intervention % (n)	Group comparison	P-value
RCTs					
Bajorek et al. ⁵³ Australia, 2016	a. Use of anticoagulants b. Proportion of patients recommended a different type of therapy c. Proportion of GPs agreeing with recommendations	January-June 2013 Control a. (total n = 187): 94.7% (177) Intervention a. (total n = 206): 89.3% (184)	12 month follow-up Control a. Not reported Intervention a. (total n = 206): 92.2% (190) b. 36.4% c. 75.2%	a. OACs in the intervention arm at baseline and follow-up	a. 0.02
Arts et al. ⁵⁴ The Netherlands, 2017	a. Proportion of patients treated according to the Dutch guidelines. b. Proportion of patients on OACs at baseline and follow-up	01/10/2013 Control a. (total n = 235): 42% (99) b. 40% (94) Intervention a. (total n = 496): 50% (248) b. 48% (238)	01/09/2014 Control a. (Total n = 259): 50% (130) b. 51% (132) Intervention a. (Total n = 522): 55% (287) b. 60% (313)	a. between group difference at baseline: 8% between group difference at follow-up: 5% b. between group difference at baseline: 8% between group difference at follow-up: 9%	a. Chi sq. between group difference at baseline: 0.04 Chi sq. between group difference at follow-up: 0.23 a. Cluster analysis between groups: 0.21 b. Chi sq. between group difference at baseline: 0.05 Chi sq. between group difference at follow-up: 0.02
Holt et al. ⁵⁵ UK, 2017	Proportion of patients eligible for OAC who were currently prescribed an OAC (CHADS ₂ ≥ 2)	20/02/2014 Control 61.9% (9.89) Intervention 63.5% (8.85)	a. 6 month follow-up Control 63.9% (SD 9.46) Intervention 66.3% (SD 9.25) b. 12 month follow-up Control: 67.8% Intervention: 65.9%	a. baseline to 6 months adjusted for baseline prescribing mean difference [95% confidence interval]: 1.21% [-0.72 to 3.13] b. baseline to 12 month adjusted for baseline prescribing mean difference [95% confidence interval]: 1.79% [-0.82 to 4.41]	a. 0.213 b. 0.173
Controlled studies					
Jackson et al. ⁵⁶ Australia, 2004	a. Percentage of eligible patients receiving warfarin upon hospital admission b. Percentage of eligible patients receiving warfarin upon hospital discharge c. All prescriptions dispensed in area (DDDs per 1000 of population)	Pre-intervention (01/02/2001 - 31/01/2002) Receiving warfarin: Intervention a. On admission total 33% (n = 81/245); high risk 33% (n = 64/192); high risk without contraindications 39% (n = 50/127); intermediate risk 30% (n = 11/37) b. On discharge total 39% high risk 40% high risk without contraindications: 49% c. Prescriptions dispensed Control region: 1127 Intervention region: 1124	Post-intervention (01/02/2002 - 31/01/2003) Receiving warfarin: Intervention a. On admission total 43% (n = 67/157); high risk 46% (n = 58/125); high risk without contraindications 53% (n = 46/87); intermediate risk 36% (n = 9/25) b. On discharge total 51% high risk 56% high risk interventions 64% c. Prescriptions dispensed Control region: 1149 Intervention region: 1191	Performed comparisons between all different group combinations	a. On admission (pre- to post-intervention) total 0.05; high risk 0.02; high risk without contraindications 0.05; intermediate risk 0.60 b. On discharge (pre- to post-intervention) total <0.05; high risk <0.01; high risk without contraindications <0.05; c. Dispensed prescriptions Intervention region: pre- versus post <0.001 Control region: pre- versus post <0.001 Intervention vs control region pre-intervention: 0.34 Intervention vs control region post-intervention: <0.001

(Continued)

Supplementary Table S2 (Continued)

Author	Outcome measure	Baseline or pre-intervention % (n)	Follow-up or post-intervention % (n)	Group comparison	P-value
Touchette et al. ⁵⁷ USA, 2008	a. Percentage of patients receiving warfarin in-hospital at discharge b. Percentage of patients with a discharge plan for warfarin use c. Percentage of patients in planned or actual warfarin use at discharge (high risk according to Chest 2004 guidelines ⁵⁸)	Not reported	Control (01/05/2001–25/07/2001) a. 41.8% (n = 41/98) b. 56.1% (n = 55/98) c. 57.1% (n = 56/98) Intervention (20/09/2001–28/02/2002) a. 45.5% (n = 70/154) b. 77.9% (n = 120/154) c. 78.6% (n = 121/154)	Between group difference a. 3.7% b. 21.8% c. 21.5%; OR 2.46 [95% CI, 1.63–3.74]	a. 0.60 b. <0.01 c. <0.01
Hendriks et al. ⁵⁹ Netherlands, 2010	The percentage of patients receiving VKA treatment (according to the ACC/AHA/ESC AF guidelines ⁶⁰ ; control group: 2001; intervention group: 2006)	Not reported	Control 2003–2004 CHADS ₂ = 0 39% (n = 7/18) CHADS ₂ = 1 93% (n = 28/30) CHADS ₂ > 1 80% (n = 42/52) In high-risk patients appropriate treatment was given to 79% (41/52) Intervention 06/2006–04/2007 CHADS ₂ = 0 18% (n = 6/34) CHADS ₂ = 1 64% (n = 25/39) CHADS ₂ > 1 90% (n = 34/38) In high-risk patients appropriate treatment was given to 97% (n = 37/38)	Between group difference CHADS ₂ = 0 21% CHADS ₂ = 1 29% CHADS ₂ > 1 10% In high-risk patients 18%	Difference in therapy per CHADS ₂ score <0.001 Difference in high-risk patients <0.05
Boriani et al. ⁶¹ Italy, 2012	Percentage of patients on OAC therapy at the end of the observational period (≤ 48 months) (CHADS ₂ ≥ 1)	Control 46.9% (n = 693/1477) Intervention 46.1% (n = 904/1961)	Control 56.8% (n = 258/454) (Intervention during the stroke risk evaluation phase 69.4% (n = 474/683) Intervention: final follow-up 72.6% (n = 496/683))	Between group difference 15.8%	<0.001
Cook et al. ⁶² USA, 2015	a. Prescription of warfarin in high-risk eligible patients within 30 days of AF diagnosis (CHADS ₂ ≥ 2) b. Prescription of warfarin in all eligible patients within 30 days of AF diagnosis (CHADS ₂ ≥ 2) c. Frequency of an appropriate medication prescription (warfarin for any warfarin-eligible patient, or aspirin for warfarin-eligible low-risk patients [CHADS ₂ < 2]).	Control: (12/2008–02/2009) a. High risk (CHADS ₂ ≥ 2) 36% (n = 34/94) b. Not provided c. 43% (n = 85/196)	Intervention: (12/2009–02/2010) a. High risk (CHADS ₂ ≥ 2) 27% (n = 34/125) b. Not provided c. 45% (n = 109/244)	a. Between group difference in high-risk patients OR 0.66 [95% CI, 0.37–1.17] b. Between group difference in all warfarin-eligible patients Adjusted OR 0.91 [95% CI, 0.60–1.38] c. Between group difference in appropriate prescription OR 1.05 [95% CI, 0.72–1.54]; adjusted OR 1.12 [95% CI, 0.76–1.66]	a. Difference in high-risk patients 0.16 b. Difference in all warfarin-eligible patients 0.65 c. Between group difference in appropriate prescription 0.78 adjusted: 0.57

Supplementary Table S2 (Continued)

Author	Outcome measure	Baseline or pre-intervention % (n)	Follow-up or post-intervention % (n)	Group comparison	P-value
Cross-sectional studies					
Falces et al. ⁶³ Spain, 2011	Percentage prescription of anticoagulation therapy (ACC/AHA/ESC AF guidelines ⁶⁰)	Usual care: (Specialist units 01/2008–12/2008) 69.3% (n = 201/290) (Univariate analysis)	Integrated care: Primary care 01/2008–12/2009; specialist units 01/2009–12/2009) 94.6% (n = 211/223) (Univariate analysis)	Logistic regression model: adjusted OR 7.1 [95% CI, 3.8–13.5]	<0.001 for univariate analysis and logistic regression
Before-after studies					
Sobreques et al. ⁶⁴ Spain, 2002	Percentage of eligible patients taking acenocumarol	Pre-intervention 70.5% (total n = 53)	Post-intervention 88.6% (total n = 53)	Between group difference 18.1%	<0.01
Lowdon et al. ⁶⁵ UK, 2004	Percentage of eligible patients prescribed anticoagulants	Pre-intervention (01/01–04/02) total 31.4% (n = 38/121); eligible patients only (no contra- indications) 43.7% (n = 38/87); total high risk 39.6% (n = 36/91); eligible high risk 52.2% (n = 36/69)	Post-intervention (05/02–12/02) total 54.5% (n = 30/55); eligible patients only (no contra- indications) 90.9% (n = 30/33); total high risk 62.8% (n = 27/43); eligible high risk 93.1% (n = 27/29)	Between group difference total 23.1%; eligible patients only (no contraindications) 47.2%	only reported for total <0.01 and total eligible <0.001
Bajorek et al. ⁶⁶ Australia, 2005	Percentage of patients receiving warfarin (± aspirin)	Pre-intervention On admission 20.7% (n = 45/218)	Post-intervention a. At discharge 17.4% (n = 38/218) b. At 3 month follow-up 16.1 (30/187) c. At 6 month follow-up 16.5 (30/184)	Between group difference post-intervention a. 3.3%	a. 0.39
Bo et al. ⁶⁷ Italy, 2007	Increase in appropriate OAC prescription at discharge	Pre-intervention Year 2000 On admission OAC strongly recommended: 36.8% Year 2000 At discharge OAC strongly recommended: 56.6% with OAC (n = 60/106)	Post-intervention Year 2004 On admission OAC strongly recommended: 58.1% Year 2004 At discharge OAC strongly recommended: 81.9% (n = 86/105)	Between groups absolute difference at discharge in OAC strongly recommended group 25.3% (95%CI: 15% 35%). Adjusted OR for OAC prescription at discharge 2.11 [95% CI, 1.47 3.04]	no p values provided
Coll-Vinent et al. ⁶⁸ Spain, 2007	a. Percentage of patients receiving anticoagulation treatment b. No anticoagulation when this is indicated	The pre-intervention period (June 2004) a. Before visit in the pre-intervention period: 53% (n = 154/293) a. After visit in the pre-intervention period: 52% (n = 151/293) b. Before visit in the pre-intervention period: 25% (n = 74/293) b. After visit in the pre-intervention period: 24% (69/293)	The post-intervention period (June 2005) a. Before visit in the post-intervention period: 58% (n = 155/267) a. After visit in the post-intervention period: 62% (n = 163/267) b. Before visit in the post-intervention period: 13% (n = 36/267) b. After visit in the post-intervention period: 10% (n = 25/267)	a. Between group difference: After visit between pre- and post-intervention periods: 10% b. Between group difference: After visit between pre- and post-intervention periods: -14%	a. Not reported b. Not reported

(Continued)

Supplementary Table S2 (Continued)

Author	Outcome measure	Baseline or pre-intervention % (n)	Follow-up or post-intervention % (n)	Group comparison	P-value
Jackson et al. ⁶⁹ Australia, 2011	Proportion of eligible patients receiving warfarin	Pre-intervention (02/2004 - 09/2004) On admission: high risk 31% (n = 76/248); moderate risk 30% (n = 22/73); low risk 16% (n = 3/19); total 30% (n = 101/340) At discharge: high risk 30% (n = 76/259); moderate risk 33% (n = 26/80); low risk 16% (n = 4/35); total 29% (n = 106/364)	Post-intervention (10/2004 - 02/2006) On admission: high risk 44% (n = 47/107); moderate risk 50% (n = 6/12); low risk 0% (n = 0/3); total 43% (n = 53/122) At discharge: high risk 57% (n = 65/115); moderate risk 80% (n = 13/16); low risk 0% (n = 0/3); total 58% (n = 78/134)	Performed comparisons between all different group combinations	Between study arms on admission: high risk <0.01; moderate risk 0.15; low risk no p-value; total 0.004 Between study arms at discharge: high risk <0.0001; moderate risk 0.0004; low risk no p-value; total 0.0008 Admission vs discharge: Pre-intervention: no significant difference Post-intervention: total 0.05; high risk 0.04; moderate/low risk no p-value
Oliveira et al. ⁷⁰ Portugal, 2014	a. Percentage of patients prescribed appropriate prophylactic therapy based on risk-scores (94% with CHA ₂ DS ₂ -VASc ≥ 2) b. OACs	Pre-intervention (01/05/2012–04/05/2012) a: 49.5% (n = 52/105) b: 46.4% (n = 45/97)	Post-intervention (03/09/2012–07/09/2012) a: 60% (n = 57/95) b: 56.3% (n = 49/87)	Between group difference a. "This means an increase of 21.2% in the number of patients receiving appropriate therapy compared to the first assessment" b. no comparison	Not reported
Robson et al. ⁷¹ UK, 2014	Percentage of patients with AF and CHA ₂ DS ₂ -VASc ≥ 1 on anticoagulants	Pre-intervention: (04/2008) 50.8% (n = 1943/3825) Pre-intervention: 04/2011 52.6% (n = 2085/3964) (Intervention commenced 04/2011)	Post-intervention: (04/2013) 59.8% (n = 2492/4168)	Between group difference: Pre-intervention to pre-intervention 2008 versus 2011: 2.2% Immediately pre-intervention to post-intervention 2011 versus 2013: 7.2% Difference in slope of the trends: 1.63 [95% CI, 1.32 - 1.94] p = < 0.001	Pre-intervention to pre-intervention: 2008 versus 2011: 0.184 Pre-intervention to post-intervention: 2011 versus 2013: <0.001
Das et al. ⁷² UK, 2015	Overall proportion of eligible patients receiving anticoagulation (CHA ₂ DS ₂ or CHA ₂ DS ₂ -VASc ≥ 1)	Pre-intervention 77% (n = 4187/5471)	Post-intervention 95% (n = 5207/5471)	Between group difference 18%	<0.0001
Hsieh et al. ⁷³ Taiwan, 2016	Percentage of discharge prescription of oral anticoagulants for eligible AF	Pre-intervention (05/2006–07/2008) 32.1% (total n = 9612)	During- intervention (08/2010–07/2011) 64.1% (total n = 7492)	Between group difference 32%	<0.001
Wang et al. ⁷⁴ Australia, 2017	a. Proportion of participants receiving OACs (Warfarin and NOACs) b. Level of HCP agreement with tools recommendations	Pre-intervention a. Total n = 251 OAC 50.5% (126); Warfarin 30.3% (76) NOAC 20.0% (50)	Post-intervention a. Total n = 251 OAC 70.0% (176); Warfarin 40.0% (76) NOAC 30.0% (54) (Interpreted from a graph) b. Agreed whether eligible for OACs: 199 (79.3%) b. Agreed with recommended therapy 132 (52.6%)	Change in patient use of OACs (in eligible patients according to risk assessment tool)	a. Change in Warfarin use p < 0.001 a. Change in NOAC use p < 0.001 b. Agreement between HCPs and tool re use of anticoagulants vs other therapy p < 0.001

Abbreviations: AF, atrial fibrillation; CHADS₂ and CHA₂DS₂-VASc, scoring schemes for stroke risk assessment; CI, confidence interval; HCP, healthcare professional; OAC, oral anticoagulants; OR, odds ratio; SD, standard deviation; VKA, Vitamin K antagonists.

References

- Makowski TM, Jacobson AK, Hildebrand SW, Ferry DR, Heywood JT. Impact of computerized tracking on increasing the proportion of atrial-fibrillation patients receiving warfarin anticoagulation for stroke prevention. *Circulation* 1994;90(04):473
- Steffensen FH, Sørensen HT, Olesen F. Impact of local evidence-based clinical guidelines—a Danish intervention study. *Fam Pract* 1997;14(03):209–215
- Gaughan GL. The use of practitioner education and a warfarin monitoring service to improve anticoagulation practices. *Arch Intern Med* 2000;160(15):2401–2402, author reply 2403
- Valeti V, Horton L, Schwartz J, Lopez-Candales A. A simple intervention to improve physician practices regarding antithrombotic therapy in patients with atrial fibrillation. *J Am Coll Cardiol* 2000;35(02):102A
- Batty G, Osborne CA, Hooper R, Jackson S. Investigation of intervention strategies to increase the appropriate use of antithrombotics in elderly hospital inpatients with atrial fibrillation. *J Clin Governance* 2001;9(03):115–122
- O'Rourke A, Fox N, Field R. A survey of education and training for clinical governance leads and Caldicott Guardians in primary care in Trent Region. *Journal of Clinical Governance*. 2001;9(3):137–142 136p
- Elliott RA, Woodward MC, Osborne CA. Antithrombotic prescribing in atrial fibrillation: application of a prescribing indicator and multidisciplinary feedback to improve prescribing. *Age Ageing* 2002;31(05):391–396
- Jackson SL, Vial JH, Peterson GM. Community-based educational intervention improves Antithrombotic drug use in atrial fibrillation. *Circulation* 2003;108(17):786
- Batty GM, Grant RL, Aggarwal R, et al. National clinical sentinel audit of evidence-based prescribing for older people. *J Eval Clin Pract* 2004;10(02):273–279
- Alberts MJ, Easton JD. Stroke Best Practices: a team approach to evidence-based care. *J Natl Med Assoc* 2004;96(4, Suppl):5S–20S
- Kiechl S. Prevention of stroke in atrial fibrillation: Implementation of study results in practice. *Wien Klin Wochenschr* 2004;116(24):817–819
- Claes N, Buntinx F, Vijgen J, et al. The Belgian improvement study on oral anticoagulation therapy: A randomized clinical trial. *Eur Heart J* 2005;26(20):2159–2165
- Wright J, Bibby J, Eastham J, et al. Multifaceted implementation of stroke prevention guidelines in primary care: cluster-randomised evaluation of clinical and cost effectiveness. *Qual Saf Health Care*. 2007;16(1):51–59 59p
- Schwarz K, Morike K, Meisner C, Fux R, Gleiter CH. Improving guideline adherence of antithrombotic therapy in patients with chronic atrial fibrillation: A prospective interventional cohort study. *Basic Clin Pharmacol* 2009;104(06):491–492
- Albert NM, Fonarow GC, Yancy CW, et al. Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). *Am J Cardiol* 2010;105(12):1773–1779
- Bishop TF, Federman AD, Ross JS. Physician incentives to improve quality and delivery of high-quality ambulatory medical care. *J Gen Intern Med* 2011;26:S68
- Szabo I, Mihaly GY, Erdelyi ZS. Antithrombotic therapy in chronic atrial fibrillation: Can enlightenment and education for stroke prevention in a busy emergency department be effective? *Eur Heart J* 2011;32:462
- Boriani G, Lunati M, Gasparini M, et al. A medical care program to improve oral anticoagulation use by leveraging atrial fibrillation diagnostic capabilities in implantable cardioverter defibrillators: the ANGELS of AF Project. *Eur Heart J* 2011;32:562
- Healicon R, Barrett J, Fay M, et al. The use of oral anti-coagulants in the management of atrial fibrillation. National data from guidance on risk assessment and stroke prevention in atrial fibrillation. *Europace* 2011;13:iv3
- Hendriks JML, de Wit R, Crijns HJGM, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. *Eur Heart J* 2012;33(21):2692–2699
- Boriani G, Santini M, Lunati M, et al; Italian Clinical Service Project. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. *Circ Cardiovasc Qual Outcomes* 2012;5(02):182–188
- Larsen SL, Sønderstrup D, Sønderstrup J, Toft JC. [Clinical guidelines for antithrombotic therapy of patients with atrial fibrillation can be implemented in general practice by means of data capture]. *Ugeskr Laeger* 2012;174(38):2227–2229
- Skanes A, Bell A. Knowledge transfer at point-of-care: Investigating new strategies for disseminating guideline recommendations. *Can J Cardiol* 2013;29(10, Suppl 1):S259
- Samani A, Das S, Khan S. Improved awareness and management of thromboprophylaxis in atrial fibrillation in an elderly care population over a seven year period. *Age Ageing* 2013;42:ii6
- Gadzhanova SV, Roughhead EE, Bartlett MJ. Improving cardiovascular disease management in Australia: NPS MedicineWise. *Med J Aust* 2013;199(03):192–195
- Arts DL, Abu-Hanna A, Büller HR, Peters RJG, Eslami S, van Weert HCPM. Improving stroke prevention in patients with atrial fibrillation. *Trials* 2013;14:193
- Jeng JS, Lien LM, Lee TH, et al. Quality improvement in acute ischemic stroke care in taiwan: The breakthrough collaborative in stroke. *Stroke* 2013;44(02):
- Beadles CA, Hassmiller Lich K, Viera AJ, Greene SB, Brookhart MA, Weinberger M. A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. *BMJ Open* 2014;4(02):e003960
- Po HL, Yu HF, Lin HC, et al. Improvement in prescription frequency of oral anticoagulant for secondary stroke prevention in the breakthrough series-stroke. *Cerebrovasc Dis* 2014;38:97
- Grant AM, Guthrie B, Dreischulte T. Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study. *BMJ Open* 2014;4(01):e004153
- Alkhalil M, Cromie N. Education in atrial fibrillation. *Ir J Med Sci* 2014;183(08, Suppl 1):S419
- Skolarus LE, Morgenstern LB, Scott PA, et al. An emergency department intervention to increase warfarin use for atrial fibrillation. *J Stroke Cerebrovasc Dis* 2014;23(02):199–203
- Sibai M-S, Bellarbre F, Ghazali N, et al. [Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation]. *Geriatr Psychol Neuropsychiatr Vieil* 2014;12(01):20–24
- Das M, Panter L, Connor N, Mills J, Gupta D. The primary care atrial fibrillation (PCAF) service: Consultant-led anticoagulation assessment clinics in the primary care setting increase the uptake of anticoagulation therapy in AF patients at high-risk of stroke. *Europace* 2014;16:iii16
- Fuenzalida C, Coll-Vinent B, Navarro M, Cervera Á, Camafort M, Mont L; En Nombre de la Unidad de Fibrilación Auricular del Hospital Clínic de Barcelona. [Temporal evolution of treatment of patients with atrial fibrillation in a urban health care area]. *Med Clin (Barc)* 2015;144(11):483–486
- Daacke I, Hau N, Williams J, Natarajan I. Atrial fibrillation and anticoagulation service run by a clinical nurse specialist. *Value Health* 2015;18(07):A400
- Akhavain RM, Sklenar J, Minnier J, Heitner S. Efficacy of clinical notifications to health care providers in management of heart failure patients. *Circulation* 2015;•••:132no pagination
- Garber JL, Willenborg KL, Rose AE. Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection. *J Thromb Thrombolysis* 2015;40(02):248–254

- 39 Zheng Q, Aneke-Nash C, Halperin JL, Vorchheimer DA. Novel oral anticoagulant availability increases appropriate use of anticoagulants for nonvalvular atrial fibrillation in clinical practice. *J Am Coll Cardiol* 2016;67(13, Suppl 1):787
- 40 Eckman MH, Lip GY, Wise RE, et al. Impact of an atrial fibrillation decision support tool (AFDST) on thromboprophylaxis for atrial fibrillation. *J Gen Intern Med* 2016;31(2, SUPPL. 1):S258–S259
- 41 Eckman MH, Lip GYH, Wise RE, et al. Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. *Am Heart J* 2016;176:17–27
- 42 Abidi SR, Cox J, Abusharekh A, Hashemian N, Abidi SS. A digital health system to assist family physicians to safely prescribe NOAC medications. *Stud Health Technol Inform* 2016;228:519–523
- 43 Lee TM, Ivers NM, Bhatia S, et al. Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. *Implement Sci* 2016;11(01):159
- 44 Rao MP, Ciobanu AO, Lopes RD, et al. A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. *Am Heart J* 2016;176:107–113
- 45 Willis TA, Hartley S, Glidewell L, et al; ASPIRE programme. Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting 'high impact' clinical practice recommendations in general practice. *Implement Sci* 2016;11:25
- 46 Czernik Z, Cheung D, Cumbler EU. Accelerating the pace of change: Standardizing anticoagulation practice for the elderly in the era of direct oral anticoagulants. *J Gen Intern Med* 2016;31(2, SUPPL. 1):S862–S863
- 47 Cloutier J, Khoo C, Hiebert B, Wassef A, Seifer C. Physician decision making in anticoagulating atrial fibrillation: A prospective survey evaluating a physician alert system for atrial fibrillation detected on cardiac implantable electronic devices. *J Am Coll Cardiol* 2016;67(13, SUPPL. 1):837
- 48 Amiri M, Kargar M, Borhanihaghighi A, Soltani F, Zare N. The effect of nurse-led care on stability time in therapeutic range of INR in ischemic stroke patients receiving warfarin. *Appl Nurs Res* 2017;33:96–101
- 49 Barmano N, Walfridsson U, Walfridsson H, Karlsson JE. Structured care of patients with atrial fibrillation improves guideline adherence. *J Atr Fibrillation* 2016;9(04):1498
- 50 Rose AJ, Park A, Gillespie C, et al. Results of a regional effort to improve warfarin management. *Ann Pharmacother* 2017;51(05):373–379
- 51 Karlsson LO, Nilsson S, Charitakis E, et al. Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting. *Am Heart J* 2017;187:45–52
- 52 Virdee MS, Stewart D. Optimizing the use of oral anticoagulant therapy for atrial fibrillation in primary care: a pharmacist-led intervention. *Int J Clin Pharm* 2017;39(01):173–180
- 53 Bajorek BV, Magin PJ, Hilmer SN, Krass I. Optimizing stroke prevention in patients with atrial fibrillation: A cluster-randomized controlled trial of a computerized antithrombotic risk assessment tool in Australian general practice, 2012–2013. *Prev Chronic Dis* 2016;13:E90
- 54 Arts DL, Abu-Hanna A, Medlock SK, van Weert HC. Effectiveness and usage of a decision support system to improve stroke prevention in general practice: A cluster randomized controlled trial. *PLoS One* 2017;12(02):e0170974
- 55 Holt TA, Dalton A, Marshall T, et al. Automated software system to promote anticoagulation and reduce stroke risk: Cluster-randomized controlled trial. *Stroke* 2017;48(03):787–790
- 56 Jackson SL, Peterson GM, Vial JH. A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. *Ann Pharmacother* 2004;38(11):1794–1799
- 57 Touchette DR, McGuinness ME, Stoner S, Shute D, Edwards JM, Ketchum K. Improving outpatient warfarin use for hospitalized patients with atrial fibrillation. *Pharm Pract (Granada)* 2008;6(01):43–50
- 58 Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest* 2004;126(3, Suppl):429S–456S
- 59 Hendriks JLM, Nieuwlaet R, Vrijhoef HJM, de Wit R, Crijns HJGM, Tieleman RG. Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program. *Neth Heart J* 2010;18(10):471–477
- 60 Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Europace* 2006;8(09):651–745
- 61 Boriani G, Santini M, Lunati M, et al; Italian Clinical Service Project. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project. *Circ Cardiovasc Qual Outcomes* 2012;5(02):182–188
- 62 Cook DA, Enders F, Caraballo PJ, Nishimura RA, Lloyd FJ. An automated clinical alert system for newly-diagnosed atrial fibrillation. *PLoS One* 2015;10(04):e0122153
- 63 Falces C, Andrea R, Heras M, et al. [Integration between cardiology and primary care: impact on clinical practice]. *Rev Esp Cardiol* 2011;64(07):564–571
- 64 Sobrequès J, Espinasa J, Cebrià J. [Effectiveness of an intervention programme to improve oral anti-coagulation treatment for patients with chronic auricular fibrillation in a health district]. *Aten Primaria* 2002;30(09):588–589
- 65 Lowdown DW, Harper JR, Gillespie ND. Improving thromboprophylaxis in elderly patients with non-valvular atrial fibrillation. *Scott Med J* 2004;49(04):148–150
- 66 Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. *J Am Geriatr Soc* 2005;53(11):1912–1920
- 67 Bo S, Valpreda S, Scaglione L, et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. *BMC Public Health* 2007;7:203
- 68 Coll-Vinent B, Pacheco G, Junyent M, et al. [Impact of implementing common guidelines at different care levels in a healthcare area on the improvement of atrial fibrillation treatment]. *Rev Esp Cardiol* 2007;60(04):392–403
- 69 Jackson SL, Peterson GM. Stroke risk assessment for atrial fibrillation: hospital-based stroke risk assessment and intervention program. *J Clin Pharm Ther* 2011;36(01):71–79
- 70 Oliveira R, Grilo S, Moreira C, et al. A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. *Rev Port Cardiol* 2014;33(02):89–94
- 71 Robson J, Dostal I, Mathur R, et al. Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts. *Br J Gen Pract* 2014;64(622):e275–e281
- 72 Das M, Panter L, Wynn GJ, et al. Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK. *BMJ Open* 2015;5(12):e009267
- 73 Hsieh F-I, Jeng J-S, Chern C-M, et al; BTS-Stroke Investigators. Quality improvement in acute ischemic stroke care in Taiwan: The breakthrough collaborative in stroke. *PLoS One* 2016;11(08):e0160426
- 74 Wang Y, Bajorek B. Pilot of a Computerised Antithrombotic Risk Assessment Tool Version 2 (CARATV2.0) for stroke prevention in atrial fibrillation. *Cardiol J* 2017;24(02):176–187